Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Published:March 12, 2015DOI:


      IL-23 is associated with plaque psoriasis susceptibility and pathogenesis. BI 655066 is a fully human IgG1 mAb specific for the IL-23 p19 subunit.


      This first-in-human proof-of-concept study evaluated the clinical and biological effects of BI 655066 in patients with moderate-to-severe plaque psoriasis.


      We performed a single-rising-dose, multicenter, randomized, double-blind, placebo-controlled, within-dose cohort phase I trial. Patients received 0.01, 0.05, 0.25, 1, 3, or 5 mg/kg BI 655066 intravenously, 0.25 or 1 mg/kg BI 655066 subcutaneously, or matched placebo. The primary objective was safety evaluation.


      Thirty-nine patients received single-dose BI 655066 intravenously (n = 18) or subcutaneously (n = 13) or placebo (n = 8). Adverse events were reported with similar frequency in the BI 655066 and placebo groups. Four serious adverse events (not considered treatment related) were reported among BI 655066–treated patients. BI 655066 was associated with clinical improvement from week 2 and maintained for up to 66 weeks after treatment. At week 12, 75%, 90%, and 100% decreases in the Psoriasis Area and Severity Index were achieved by 87%, 58%, and 16% of BI 655066–treated patients (any dose), respectively, versus none receiving placebo. BI 655066 treatment resulted in reduced expression of lesional skin genes associated with IL-23/IL-17 signaling pathways and normalization of psoriatic lesion gene expression profiles to a profile approaching that of nonlesional skin. Significant correlation between treatment-associated molecular changes and psoriasis area and severity index improvement was observed (r = 0.73, P = 2 × 10−6).


      BI 655066 was well tolerated and associated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis, supporting a central role for IL-23 in psoriasis pathogenesis.

      Key words

      Abbreviations used:

      AE (Adverse event), AUEC (Area under the effect curve), DC-LAMP (Dendritic cell lysosome-associated membrane glycoprotein), Emax (Maximum effect), FC (Fold change), MACE (Major adverse cardiovascular event), PASI (Psoriasis Area and Severity Index), RNA-seq (RNA sequencing), SAE (Serious adverse event), sPGA (Static Physician Global Assessment), TIA (Transient ischemic attack)
      To read this article in full you will need to make a payment


        • Lowes M.A.
        • Suarez-Farinas M.
        • Krueger J.G.
        Immunology of psoriasis.
        Annu Rev Immunol. 2014; 32: 227-255
      1. Psoriasis: report by the secretariat. World Health Organization Executive Board.
        (Available at:) (Accessed December 2014)
        • Stern R.S.
        • Nijsten T.
        • Feldman S.R.
        • Margolis D.J.
        • Rolstad T.
        Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
        J Investig Dermatol Symp Proc. 2004; 9: 136-139
        • Pfohler C.
        • Muller C.S.
        • Vogt T.
        Psoriasis vulgaris and psoriasis pustulosa—epidemiology, quality of life, comorbidities and treatment.
        Curr Rheumatol Rev. 2013; 9: 2-7
        • Nestle F.O.
        • Kaplan D.H.
        • Barker J.
        N Engl J Med. 2009; 361: 496-509
        • Menter A.
        • Gottlieb A.
        • Feldman S.R.
        • Van Voorhees A.S.
        • Leonardi C.L.
        • Gordon K.B.
        • et al.
        Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
        J Am Acad Dermatol. 2008; 58: 826-850
        • Cargill M.
        • Schrodi S.J.
        • Chang M.
        • Garcia V.E.
        • Brandon R.
        • Callis K.P.
        • et al.
        A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.
        Am J Hum Genet. 2007; 80: 273-290
        • Nair R.P.
        • Duffin K.C.
        • Helms C.
        • Ding J.
        • Stuart P.E.
        • Goldgar D.
        • et al.
        Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.
        Nat Genet. 2009; 41: 199-204
        • Fredriksson T.
        • Pettersson U.
        Severe psoriasis—oral therapy with a new retinoid.
        Dermatologica. 1978; 157: 238-244
        • Robinson A.
        • Kardos M.
        • Kimball A.B.
        Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
        J Am Acad Dermatol. 2012; 66: 369-375
        • Langley R.G.
        • Ellis C.N.
        Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
        J Am Acad Dermatol. 2004; 51: 563-569
        • Fredriksson T.
        • Pettersson U.
        Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359.
        Dermatologica. 1979; 158: 60-64
        • Huang D.W.
        • Sherman B.T.
        • Tan Q.
        • Collins J.R.
        • Alvord W.G.
        • Roayaei J.
        • et al.
        The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists.
        Genome Biol. 2007; 8: R183
        • Edgar R.
        • Domrachev M.
        • Lash A.E.
        Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.
        Nucleic Acids Res. 2002; 30: 207-210
        • Li B.
        • Tsoi L.C.
        • Swindell W.R.
        • Gudjonsson J.E.
        • Tejasvi T.
        • Johnston A.
        • et al.
        Transcriptome analysis of psoriasis in a large case-control sample: RNA-Seq provides insights into disease mechanisms.
        J Invest Dermatol. 2014; 134: 1828-1838
        • Chiricozzi A.
        • Saraceno R.
        • Chimenti M.S.
        • Guttman-Yassky E.
        • Krueger J.G.
        Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?.
        Expert Opin Ther Targets. 2014; 18: 513-525
        • Papp K.A.
        • Langley R.G.
        • Sigurgeirsson B.
        • Abe M.
        • Baker D.R.
        • Konno P.
        • et al.
        Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
        Br J Dermatol. 2013; 168: 412-421
        • Leonardi C.
        • Matheson R.
        • Zachariae C.
        • Cameron G.
        • Li L.
        • Edson-Heredia E.
        • et al.
        Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
        N Engl J Med. 2012; 366: 1190-1199
        • Papp K.A.
        • Leonardi C.
        • Menter A.
        • Ortonne J.P.
        • Krueger J.G.
        • Kricorian G.
        • et al.
        Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
        N Engl J Med. 2012; 366: 1181-1189
        • Krueger G.G.
        • Langley R.G.
        • Leonardi C.
        • Yeilding N.
        • Guzzo C.
        • Wang Y.
        • et al.
        A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
        N Engl J Med. 2007; 356: 580-592
        • Sofen H.
        • Smith S.
        • Matheson R.T.
        • Leonardi C.L.
        • Calderon C.
        • Brodmerkel C.
        • et al.
        Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
        J Allergy Clin Immunol. 2014; 133: 1032-1040
        • Smith C.H.
        • Anstey A.V.
        • Barker J.N.
        • Burden A.D.
        • Chalmers R.J.
        • Chandler D.
        • et al.
        British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
        Br J Dermatol. 2005; 153: 486-497
        • Ramirez-Fort M.K.
        • Levin A.A.
        • Au S.C.
        • Gottlieb A.B.
        Continuous versus intermittent therapy for moderate-to-severe psoriasis.
        Clin Exp Rheumatol. 2013; 31: S63-S70
        • Brezinski E.A.
        • Armstrong A.W.
        Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies.
        Semin Cutan Med Surg. 2014; 33: 91-97
        • Mehta N.N.
        • Yu Y.
        • Pinnelas R.
        • Krishnamoorthy P.
        • Shin D.B.
        • Troxel A.B.
        • et al.
        Attributable risk estimate of severe psoriasis on major cardiovascular events.
        Am J Med. 2011; 124: 775.e1-775.e6
        • Ryan C.
        • Leonardi C.L.
        • Krueger J.G.
        • Kimball A.B.
        • Strober B.E.
        • Gordon K.B.
        • et al.
        Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
        JAMA. 2011; 306: 864-871
        • Papp K.A.
        • Griffiths C.E.
        • Gordon K.
        • Lebwohl M.
        • Szapary P.O.
        • Wasfi Y.
        • et al.
        Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
        Br J Dermatol. 2013; 168: 844-854


        • Zaba L.C.
        • Fuentes-Duculan J.
        • Eungdamrong N.J.
        • Abello M.V.
        • Novitskaya I.
        • Pierson K.C.
        • et al.
        Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell471 polarizing myeloid dendritic cells.
        J Invest Dermatol. 2009; 129: 79-88
        • Langley R.G.
        • Ellis C.N.
        Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
        J Am Acad Dermatol. 2004; 51: 563-569